Junik (Beclometasone Dipropionate)

Beclometasone dipropionate is an inhaled corticosteroid used to control inflammation in chronic respiratory diseases, helping patients achieve better lung function and reduce reliance on short‑acting bronchodilators.

• Asthma: improves symptom control and reduces frequency of exacerbations by decreasing airway inflammation.
• Chronic obstructive pulmonary disease (COPD): helps maintain lung function and lowers risk of flare‑ups when used as maintenance therapy.
• Prevention of asthma symptoms: provides long‑term control to reduce the need for rescue inhalers.

• Beclometasone dipropionate binds to intracellular glucocorticoid receptors in airway epithelial and inflammatory cells. The activated receptor complex moves to the nucleus and alters gene transcription, suppressing pro‑inflammatory cytokines, chemokines, and adhesion molecules while increasing anti‑inflammatory protein expression. This reduces airway edema, mucus secretion, and hyper‑responsiveness, delivering sustained anti‑inflammatory effects throughout the bronchial tree.

Adverse reactions may occur with inhaled beclometasone dipropionate. Patients should be aware of both common and serious possibilities.

Common Side Effects

• Oral candidiasis (thrush): fungal infection of the mouth.
• Hoarseness or dysphonia: voice changes after inhalation.
• Cough or throat irritation: mild irritation of the upper airway.
• Headache: occasional mild headache.
• Sore throat: discomfort in the throat region.

Serious or Rare Side Effects

• Adrenal suppression: reduced endogenous cortisol production.
• Pneumonia: increased risk of lower respiratory infection.
• Paradoxical bronchospasm: sudden worsening of breathing.
• Severe allergic reaction: anaphylaxis or angioedema.
• Growth retardation in children: potential impact on normal growth patterns.
• Ocular effects: cataract formation or glaucoma with long‑term use.

Before prescribing Junik, clinicians should consider several safety measures.

• Infection risk: assess for active respiratory infections before initiating therapy.
• Growth monitoring: regularly evaluate growth in pediatric patients.
• Spacer use: recommend a spacer device to minimize oral deposition and reduce local side effects.
• Discontinuation: avoid abrupt cessation; taper if long‑term high doses have been used.
• Systemic effects: monitor for signs of adrenal suppression, especially with high‑dose regimens.
• Store at room temperature: keep in the original packaging, protect from moisture and heat.

Beclometasone dipropionate may interact with other medicines, requiring attention to the level of interaction.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase systemic corticosteroid exposure.
• Systemic corticosteroids: additive glucocorticoid effects can raise risk of adrenal suppression.

Moderate Interactions (Monitor Closely)

• Diuretics (e.g., furosemide): may enhance hypokalemia when combined with systemic steroids.
• Non‑selective beta‑agonists: potential for reduced bronchodilator response.
• Antifungal azoles (moderate CYP3A4 inhibition): may modestly increase steroid levels.
• Antiretroviral agents with moderate CYP3A4 effect: may alter steroid metabolism.